Two COVID-19 Vaccines For Young Children Show Promise In Early Trials: Study

Two COVID-19 Vaccines For Young Children Show Promise In Early Trials: Study

The Moderna COVID-19 vaccine was among two vaccines which have shown promise of being safe to use on children during early trials. The research, published in the journal Science Immunology, suggests that vaccines for young children are likely important, safe tools to curtail the pandemic
Coronavirus Outbreak, Coronavirus Vaccine, News
- in Coronavirus Outbreak, Coronavirus Vaccine, News
0
Two COVID-19 Vaccines For Young Children Show Promise In Early Trials: StudyCOVID-19 vaccine trials are in early stages to see how safe they are for use on children (Representational)
Highlights
  • The vaccine instructs the cells to create the spike protein
  • The human immune cells recognise the protein and develop antibodies
  • The vaccines did not elicit T helper type 2 responses

New York: The Moderna COVID-19 vaccine and an experimental protein-based preventive proved to be safe and showed good antibody response against SARS-CoV-2 in a trial on baby rhesus macaques, scientists say. The research, published on Tuesday in the journal Science Immunology, suggests that vaccines for young children are likely important, safe tools to curtail the pandemic. Sallie Permar from New York-Presbyterian Komansky Children’s Hospital, US said “Safe and effective vaccines for young children will help limit the spread of COVID-19 because we know children can transmit the virus to others, whether they get sick from SARS-CoV-2 infection or remain asymptomatic. Moreover, many children have become sick and even died from the infection, with many more negatively impacted by the measures put in place to curb the spread. Thus, young children deserve protection from COVID.”

Also Read: COVID-19 Vaccine Covishield: India Will Revisit Dosage Interval Based On Emerging Data

The strong neutralising antibody response elicited by the vaccines in 16 baby rhesus macaques persisted for 22 weeks. The researchers are conducting challenge studies this year to better understand potential long-lasting protection of the vaccines.

The level of potent antibodies we observed were comparable to what has been seen in adult macaques, even though the doses were 30 micrograms instead of the 100 microgram adult doses. With the Moderna vaccine, we observed specific strong T cell responses, as well, which we know are important to limiting disease severity, said Kristina De Paris, professor at the University of North Carolina, US.

The researchers immunised two groups of 8 infant rhesus macaques at 2.2 months of age and four weeks later. Each animal received either a preclinical version of the Moderna mRNA vaccine or a protein-based vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID), US.

The mRNA vaccine delivers instructions to the body to produce the virus’s surface protein, the spike protein. The vaccine instructs the cells to create the spike protein, which the virus uses to infect and enter the human cells. The human immune cells recognise the protein and develop antibodies and other immune responses.

NIAID’s vaccine is the actual spike protein itself, which the immune system recognises in the same manner. Both vaccines elicited high magnitude of IgG neutralising antibodies against SARS-CoV-2 and spike protein-specific T cell responses, the researchers said. The vaccines did not elicit T helper type 2 responses, which can be detrimental to vaccine efficacy and safety in infants, they said. The researchers said since such responses can counter the immune response against the virus, T helper 2 responses have hindered the development of vaccines in young children.

We were sure to check for evidence of T helper 2 responses, such as IL4, in the blood plasma of all macaques to be sure neither vaccine produced such a response. We need to keep studying this, but so far we have seen no evidence of this, De Paris said.

Also Read: COVID-19 Vaccination Coverage: Tribal Districts Performing Better Than National Average, Says Union Health Ministry

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

World

19,89,21,889Cases
6,44,02,340Active
13,02,83,678Recovered
42,35,871Deaths
Coronavirus has spread to 194 countries. The total confirmed cases worldwide are 19,89,21,889 and 42,35,871 have died; 6,44,02,340 are active cases and 13,02,83,678 have recovered as on August 3, 2021 at 3:55 am.

India

3,17,26,507 30,549Cases
4,04,9588,760Active
3,08,96,354 38,887Recovered
4,25,195 422Deaths
In India, there are 3,17,26,507 confirmed cases including 4,25,195 deaths. The number of active cases is 4,04,958 and 3,08,96,354 have recovered as on August 3, 2021 at 2:30 am.

State Details

State Cases Active Recovered Deaths
Maharashtra

63,15,063 4,869

78,700 3,650

61,03,325 8,429

1,33,038 90

Kerala

34,25,473 13,984

1,65,834 2,057

32,42,684 15,923

16,955 118

Karnataka

29,08,284 1,285

24,045 123

28,47,627 1,383

36,612 25

Tamil Nadu

25,63,544 1,957

20,385 139

25,09,029 2,068

34,130 28

Andhra Pradesh

19,70,008 1,546

20,582 437

19,36,016 1,968

13,410 15

Uttar Pradesh

17,08,500 24

646 18

16,85,091 42

22,763

West Bengal

15,29,295 575

10,803 171

15,00,331 734

18,161 12

Delhi

14,36,401 51

538 44

14,10,809 95

25,054

Chhattisgarh

10,02,458 236

1,918 1

9,87,012 234

13,528 3

Odisha

9,79,737 1,032

13,318 820

9,60,386 1,785

6,033 67

Rajasthan

9,53,704 16

241 9

9,44,509 25

8,954

Gujarat

8,24,922 22

251 3

8,14,595 25

10,076

Madhya Pradesh

7,91,862 17

132 7

7,81,217 10

10,513

Haryana

7,69,956 14

703 12

7,59,614 25

9,639 1

Bihar

7,24,917 37

401 34

7,14,872 71

9,644

Telangana

6,45,997 591

8,819 54

6,33,371 643

3,807 2

Punjab

5,99,162 32

473 31

5,82,395 63

16,294

Assam

5,68,257 1,275

12,429 213

5,50,534 1,469

5,294 19

Jharkhand

3,47,223 23

239 15

3,41,855 38

5,129

Uttarakhand

3,42,198 37

574 35

3,34,261 71

7,363 1

Jammu And Kashmir

3,21,725 118

1,254 43

3,16,090 73

4,381 2

Himachal Pradesh

2,06,369 208

1,304 75

2,01,543 132

3,522 1

Goa

1,71,295 90

1,027 16

1,67,118 72

3,150 2

Puducherry

1,21,059 54

944 38

1,18,320 92

1,795

Manipur

99,872 541

9,814 591

88,480 1,120

1,578 12

Tripura

79,026 304

3,104 12

75,167 292

755

Meghalaya

65,939 350

5,843 200

58,987 537

1,109 13

Chandigarh

61,960 6

33 3

61,116 3

811

Arunachal Pradesh

48,565 305

3,508 167

44,823 469

234 3

Mizoram

40,111 748

12,316 127

27,642 618

153 3

Nagaland

28,004 59

1,300 44

26,130 99

574 4

Sikkim

26,880 126

3,323 131

23,211 256

346 1

Ladakh

20,345 5

57 0

20,081 5

207

Dadra And Nagar Haveli

10,650

15 9

10,631 9

4

Lakshadweep

10,207 12

79 4

10,078 8

50

Andaman And Nicobar Islands

7,539

6 1

7,404 1

129

Coronavirus Outbreak: Full CoverageTesting CentresFAQs

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like

Increased Risk Of Heart Attack, Stroke In First Two Weeks Following COVID-19: Lancet Study

The study published in the Lancet journal compared the occurrence of acute myocardial infarction or heart attack, and stroke in 86,742 COVID-19 patients with 3.48lakh control individuals in Sweden from February 1 to September 14, 2020